505 completed, 171 unknown, 139 terminated, 127 recruiting. 1106 Phase 2, 160 Phase 1, 62 Phase 3.
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 64 | 2026-10-20 | 2026-09-28 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-26 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-10-26 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Esophageal Adenocarcinoma | Phase 2 | Recruiting | Duke University | 60 | 2026-09-01 | 2026-09-29 |
| A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | AbbVie | 150 | 2026-09-01 | 2026-10-27 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-08-31 | 2026-06-23 |
| A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer HDM2017, Bevacizumab, Oxaliplatin - CRC, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 220 | 2026-08-18 | 2026-09-04 |
| SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma SKB500, Tislelizumab, Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 120 | 2026-08-13 | 2026-10-20 |
| Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Zolbetuximab, Durvalumab, FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) - CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 29 | 2026-08-13 | 2026-10-20 |
| Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients Ivonescimab +mFOLFOXIRI +celecoxib - Colorectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2026-08-10 | 2026-09-09 |
| A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer MRG007, 5-Fluorouracil / Leucovorin Calcium, Bevacizumab - Advanced Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Lepu Biopharma Co., Ltd. | 316 | 2026-08-01 | 2026-08-04 |
Showing 20 of 1106. Sign in to see all of them.
Colorectal Neoplasms (272) · Rectal Neoplasms (157) · Pancreatic Neoplasms (114) · Stomach Neoplasms (114) · Colonic Neoplasms (106) · Esophageal Neoplasms (87) · Neoplasm Metastasis (69) · Squamous Cell Carcinoma of Head and Neck (58) · Adenocarcinoma Of Esophagus (50) · Head and Neck Neoplasms (49) · Neoplasms (46) · Esophageal Squamous Cell Carcinoma (41) · Breast Neoplasms (38) · Carcinoma, Hepatocellular (31) · Adenocarcinoma (22)
National Cancer Institute (NCI) (35) · Sun Yat-sen University (31) · M.D. Anderson Cancer Center (24) · Fudan University (22) · ImmunityBio, Inc. (21) · Memorial Sloan Kettering Cancer Center (19) · UNICANCER (19) · GERCOR - Multidisciplinary Oncology Cooperative Group (18) · Alliance for Clinical Trials in Oncology (17) · Hoffmann-La Roche (16) · Sanofi (16) · European Organisation for Research and Treatment of Cancer - EORTC (15) · SWOG Cancer Research Network (14) · AstraZeneca (13) · Washington University School of Medicine (13)
United States (507) · China (204) · France (115) · Germany (88) · Italy (74) · Spain (71) · Canada (61) · South Korea (54) · United Kingdom (54) · Japan (51) · Belgium (46) · Taiwan (42) · Australia (39) · Poland (26) · Russia (20)
David J. Adelstein, MD (4) · Everett Vokes, MD (4) · Masahiro Asaka, MD, PhD (4) · Steven R. Alberts, MD (4) · Yelena Janjigian, MD (4) · Ashwin Somasundaram, MD (3)
PMID 32816630, PMID 40341124, PMID 21561347, PMID 23493136, PMID 26187751, PMID 28797458, PMID 34037241, PMID 36940261, PMID 40147791, PMID 10615932, PMID 12049862, PMID 12074329, PMID 12448660, PMID 12518365, PMID 12540794, PMID 12860947, PMID 14759776, PMID 15496622, PMID 15533252, PMID 15558814, PMID 15625363, PMID 15646530, PMID 15800321, PMID 15863167, PMID 15908661, PMID 16009952, PMID 16098249, PMID 16110021, PMID 16230673, PMID 16446336, PMID 16479065, PMID 16514137, PMID 16515704, PMID 16532436, PMID 16779801, PMID 16832602, PMID 16849749, PMID 16849759, PMID 16865597, PMID 16873427, PMID 16921048, PMID 17030548, PMID 17084549, PMID 17227978, PMID 17470859, PMID 17482376, PMID 17553200, PMID 17592291, PMID 17664469, PMID 17785765
U10CA032102 (12), 2017 (11), 2016 (10), 2023 (10), 2014 (8), U10CA180820 (8), 2008 (7), 2009 (7), 2018 (6), P30CA043703 (6), U10CA180888 (6), 2015 (5), 2019 (5), P30CA033572 (5), U10CA031946 (5)